Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.

Sandhoff disease is a lysosomal storage disorder characterized by G(M2) ganglioside accumulation in the central nervous system (CNS) and periphery. It results from mutations in the HEXB gene, causing a deficiency in beta-hexosaminidase. Bone marrow transplantation (BMT), which augments enzyme levels, and substrate deprivation (using the glycosphingolipid biosynthesis inhibitor N-butyldeoxynojirimycin [NB-DNJ]) independently have been shown to extend life expectancy in a mouse model of Sandhoff disease. The efficacy of combining these 2 therapies was evaluated. Sandhoff disease mice treated with BMT and NB-DNJ survived significantly longer than those treated with BMT or NB-DNJ alone. When the mice were subdivided into 2 groups on the basis of their donor bone marrow-derived CNS enzyme levels, the high enzyme group exhibited a greater degree of synergy (25%) than the group as a whole (13%). Combination therapy may therefore be the strategy of choice for treating the infantile onset disease variants.

[1]  V. Perry,et al.  Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  F. Platt,et al.  New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. , 1998, Biochemical pharmacology.

[3]  J. Crawley,et al.  Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. , 1998, The Journal of clinical investigation.

[4]  R. Dwek,et al.  Extensive Glycosphingolipid Depletion in the Liver and Lymphoid Organs of Mice Treated with N-Butyldeoxynojirimycin* , 1997, The Journal of Biological Chemistry.

[5]  V. Perry,et al.  Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. , 1997, Science.

[6]  Michael P. McDonald,et al.  Mouse models of Tay–Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism , 1995, Nature Genetics.

[7]  L. Lockman,et al.  Microglia: The Effector Cell for Reconstitution of the Central Nervous System following Bone Marrow Transplantation for Lysosomal and Peroxisomal Storage Diseases , 1995 .

[8]  S. Walkley,et al.  Bone marrow transplantation for lysosomal diseases , 1995, The Lancet.

[9]  D. Frappaz,et al.  Allogeneic bone marrow transplantation for lysosomal storage diseases , 1995, The Lancet.

[10]  R. Dwek,et al.  N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. , 1994, The Journal of biological chemistry.

[11]  R. Dwek,et al.  N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. , 1994, The Journal of biological chemistry.

[12]  J. Roder,et al.  Female transgenic mice carrying multiple copies of the human gene for S100β are hyperactive , 1993, Behavioural Brain Research.

[13]  D. Harrington.  A class of rank test procedures for censored survival data , 1982 .

[14]  D. Frappaz,et al.  Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. , 1995, Lancet.